All In Biotech

Drug Trial Radar · NCT07231471

Platelet Rich Plasma for Musculoskeletal Conditions

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Jan 1, 2035

Study completion Jan 1, 2035

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Conditions

  • Osteoarthritis (OA)
  • Osteoarthritis (OA) of the Knee
  • Osteoarthritis (OA) of the Hip
  • Osteoarthritis (OA) of the Shoulder
  • Osteoarthritis Ankle
  • Elbow Osteoarthritis
  • Epicondylitis of the Elbow
  • Plantar Fasciitis of Both Feet
  • Tendinopathy

Interventions

  • Platelet Rich Plasma InjectionBiological

    Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their blood will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.

  • Platelet Rich Plasma PreparationDevice

    The patient's blood is collected into syringes. That blood is spun in a centrifuge at high speeds, which separates their blood into layers (red blood cells, white blood cells, and plasma). The plasma portion, which contains the platelets, is transferred to a different syringe for later injection. In some cases, the plasma is spun in the centrifuge again (a "double spin" technique) to further concentrate the platelets in the plasma. The patient's blood is not exposed to air, and it is transferred by tubing between syringes with a Luer Lock connection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual analog score (pain)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Utah Orthoaedic Center

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.